00:00
Growing Money
Growing Money
USD/RUB
EUR/RUB
Releases

Fullspan Health Launches AIQ to Track Pharma Visibility in AI Search

As one-third of adults now turn to artificial intelligence for medical advice, RVO Health’s Fullspan Health platform has introduced AIQ, a proprietary tool designed to help pharmaceutical marketers measure and optimize how their brands are referenced, cited, and linked across major AI platforms like ChatGPT, Claude, and Gemini.

Fullspan Health Launches AIQ to Track Pharma Visibility in AI Search

The tool arrives as health brands struggle to maintain visibility in a digital landscape where AI search engines often act as the primary gatekeeper for patient information. AIQ provides marketers with a window into how their brand.com sites appear in AI-generated answers, offering metrics to track campaign performance and refine strategies for Agentic Experience Optimization (AEO). By leveraging Fullspan Health’s portfolio—which includes Healthline, Medical News Today, and Psych Central—brands can now identify specific gaps in their AI presence and adjust their outreach to capture high-intent users at the moment of diagnosis.

Recent data highlights the urgency of this shift. According to an analysis of prompts across key therapeutic areas, Fullspan Health properties currently appear in approximately two-thirds of AI-generated responses. In specific categories, such as migraines, the company’s content reaches an 81% citation rate. The platform also reports a significant competitive edge in niche categories; for instance, its content appeared 15.5 times more frequently than its closest competitor in recent oncology and rare disease queries. Christine Maguire, EVP and Chief Business Officer at Fullspan Health, noted that AI has become the new front door for health discovery, requiring brands to actively manage their share of voice in automated answers. AIQ is currently available across all Fullspan Health advertising products and is integrated into the company’s 2027 marketing solutions.

Share

Comments (0)

Leave a comment

No comments yet. Be the first!